M. Gorny

发表

Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.

L. Stamatatos, S. Zolla-Pazner, M. Gorny, 1997, Virology.

Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site

B. Walker, B. Haynes, S. Zolla-Pazner, 2018, JCI insight.

Antibodiesand Their Recognition by Immunotypes of a Quaternary Site of HIV-1

J. Mascola, L. Stamatatos, S. Zolla-Pazner, 2014 .

Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies

J. Mascola, L. Stamatatos, S. Zolla-Pazner, 2011, Journal of Virology.

Longitudinal Study of Primary HIV-1 Isolates in Drug-Naïve Individuals Reveals the Emergence of Variants Sensitive to Anti-HIV-1 Monoclonal Antibodies

M. Gorny, G. Vanham, Constance A U Williams, 2011, PloS one.

Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes

S. Zolla-Pazner, M. Gorny, S. Self, 2009, PloS one.

Factors Determining the Breadth and Potency of Neutralization by V3-Specific Human Monoclonal Antibodies Derived from Subjects Infected with Clade A or Clade B Strains of Human Immunodeficiency Virus Type 1

S. Zolla-Pazner, M. Gorny, A. Pinter, 2006, Journal of Virology.

Antibodies That Are Cross-Reactive for Human Immunodeficiency Virus Type 1 Clade A and Clade B V3 Domains Are Common in Patient Sera from Cameroon, but Their Neutralization Activity Is Usually Restricted by Epitope Masking

S. Zolla-Pazner, M. Gorny, A. Pinter, 2005, Journal of Virology.

Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120.

S. Zolla-Pazner, M. Gorny, S. Jeffs, 2001, Immunology letters.

Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.

J. Robinson, S. Zolla-Pazner, M. Gorny, 1997, AIDS research and human retroviruses.

The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel

S. Zolla-Pazner, M. Gorny, X. Kong, 2015, Journal of Virology.

Nonneutralizing HIV-1 gp41 Envelope Cluster II Human Monoclonal Antibodies Show Polyreactivity for Binding to Phospholipids and Protein Autoantigens

H. Liao, Laura L. Sutherland, B. Haynes, 2010, Journal of Virology.

Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens.

S. Zolla-Pazner, M. Gorny, M. Sukumaran, 2009, Structure.

Unusually Potent Neutralizing Activities Monoclonal Antibodies Possessing by Human and Rhesus Macaque of Related Quaternary Epitopes Recognized Diversity of Variable-Region Determinants Characterization of Structural Features and

S. Zolla-Pazner, M. Gorny, A. Pinter, 2011 .

Characterization of Structural Features and Diversity of Variable-Region Determinants of Related Quaternary Epitopes Recognized by Human and Rhesus Macaque Monoclonal Antibodies Possessing Unusually Potent Neutralizing Activities

S. Zolla-Pazner, M. Gorny, James E. Robinson, 2011, Journal of Virology.

A Protein HIV-gp 120 Recognized by the Discontinuous Epitope of the HIV Envelope Mass Spectrometric Characterization of a Zolla-Pazner

S. Zolla-Pazner, M. Gorny, K. Tomer, 2000 .

Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

S. Zolla-Pazner, M. Gorny, X. Kong, 2012, Virology.

Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL

S. Zolla-Pazner, M. Gorny, A. Nadas, 2015, Journal of Virology.

Book Chapter Immune Correlates of Disease Progression in Linked HIV-1 Infection

Shilei, Marcel, Arthur, 2020 .

Near full genome characterization of HIV‐1 unique recombinant forms in Cameroon reveals dominant CRF02_AG and F2 recombination patterns

M. Gorny, A. Heguy, C. Fokunang, 2019, Journal of the International AIDS Society.

Comparison of various radioactive payloads for a human monoclonal antibody to glycoprotein 41 for elimination of HIV-infected cells.

M. Gorny, J. Berman, E. Dadachova, 2020, Nuclear medicine and biology.

Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication

A. Casadevall, S. Zolla-Pazner, M. Gorny, 2012, PloS one.

Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine–Induced Anti-V2 Antibodies Alone

N. Haigwood, M. Gorny, D. Montefiori, 2021, The Journal of Immunology.

Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

N. Haigwood, S. Zolla-Pazner, M. Gorny, 2016, Vaccine.

Thermodynamic signatures of the antigen binding site of mAb 447-52D targeting the third variable region of HIV-1 gp120.

S. Zolla-Pazner, M. Gorny, X. Kong, 2013, Biochemistry.

Different Pattern of Immunoglobulin Gene Usage by HIV-1 Compared to Non-HIV-1 Antibodies Derived from the Same Infected Subject

S. Zolla-Pazner, M. Gorny, A. Nadas, 2012, PloS one.

Quaternary Epitope Specificities of Anti-HIV-1 Neutralizing Antibodies Generated in Rhesus Macaques Infected by the Simian/Human Immunodeficiency Virus SHIVSF162P4

L. Stamatatos, S. Zolla-Pazner, M. Gorny, 2010, Journal of Virology.

The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.

S. Zolla-Pazner, M. Gorny, Constance A U Williams, 2004, AIDS research and human retroviruses.

Mass Spectrometric Characterization of a Discontinuous Epitope of the HIV Envelope Protein HIV-gp120 Recognized by the Human Monoclonal Antibody 1331A1

S. Zolla-Pazner, M. Gorny, K. Tomer, 2000, The Journal of Immunology.

In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.

M. Gorny, C. Hioe, M. Visciano, 2008, Virology.

Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodies.

S. Zolla-Pazner, M. Gorny, A. Nadas, 2004, AIDS research and human retroviruses.

Generation of human monoclonal antibodies to human immunodeficiency virus.

S. Zolla-Pazner, M. Gorny, V. Gianakakos, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant.

S. Zolla-Pazner, M. Gorny, A. Prince, 1998, The Journal of infectious diseases.

Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

N. Haigwood, S. Zolla-Pazner, M. Gorny, 2017, Vaccine.

Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.

S. Zolla-Pazner, M. Gorny, M. Totrov, 2011, Structure.

Prediction of contact residues in anti-HIV neutralizing antibody by deep learning.

M. Gorny, S. Matsushita, T. Kuwata, 2020, Japanese journal of infectious diseases.

Human hybridoma technology

M. Gorny, 2012 .

Gamma heavy chain disease in man: independent structural abnormalities and reduced transcription of a functionally rearranged lambda L-chain gene result in the absence of L-chains.

M. Gorny, M. Teng, J. Buxbaum, 2000, Blood cells, molecules & diseases.

Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer.

S. Zolla-Pazner, M. Gorny, M. A. Moody, 2013, Human antibodies.

Passive immunization for the prevention and treatment of HIV infection.

S. Zolla-Pazner, M. Gorny, 1992, AIDS.

Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals

A. Casadevall, S. Zolla-Pazner, M. Gorny, 2016, Front. Med..

Presentation of HIV V3 loop epitopes for enhanced antigenicity, immunogenicity and diagnostic potential

S. Zolla-Pazner, M. Gorny, D. Birx, 1995, AIDS.

Development and characterization of a panel of anti-idiotype antibodies to 1C10 that cross-neutralize HIV-1 subtype B viruses

M. Gorny, S. Matsushita, T. Kuwata, 2022, Frontiers in Virology.

Immunoreactivity of Intact Virions of Human Immunodeficiency Virus Type 1 (HIV-1) Reveals the Existence of Fewer HIV-1 Immunotypes than Genotypes

S. Zolla-Pazner, M. Gorny, A. Nadas, 2000, Journal of Virology.

Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individuals.

S. Zolla-Pazner, M. Gorny, J. McKeating, 1997, AIDS.

Chronic lymphocytic leukemia with prostate infiltration mediated by specific clonal membrane-bound IgM.

S. Zolla-Pazner, M. Gorny, H. Furneaux, 2003, Cancer research.

Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Speciﬁc Antibodies That Potently Neutralize HIV-1 (cid:1) †§

J. Mascola, L. Stamatatos, S. Zolla-Pazner, 2011 .

Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro

S. Zolla-Pazner, M. Gorny, W. Robinson, 1991, Journal of virology.

An immuno-dot blot assay for the detection of antibody to HIV.

S. Zolla-Pazner, M. Gorny, J. Y. Xu, 1989, Journal of immunological methods.

Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.

S. Zolla-Pazner, M. Gorny, A. Buchbinder, 1992, AIDS research and human retroviruses.

The influence of high‐dose prednisone medication on autoantibody specific activity and on circulation immune complex level in cerebrospinal fluid of multiple sclerosis patients

M. Gorny, A. Wajgt, R. Jenek, 1983, Acta neurologica Scandinavica.

CSF antibodies to myelin basic protein and oligodendrocytes in multiple sclerosis and other neurological diseases

M. Gorny, D. Pleasure, Z. Wróblewska, 1983, Acta neurologica Scandinavica.

CSF antibodies to myelin basic protein and to myelin‐associated glycoprotein in multiple sclerosis. Evidence of the intrathecal production of antibodies

M. Gorny, A. Wajgt, 1983, Acta neurologica Scandinavica.

Generation of neutralizing anti-B19 parvovirus human monoclonal antibodies from patients infected with human immunodeficiency virus.

S. Zolla-Pazner, M. Gorny, M. Collett, 1993, The Journal of infectious diseases.

Effect of immunosuppressive therapy on humoral immune response in multiple sclerosis.

M. Gorny, S. Ochudło, L. Szczechowski, 1989, Acta medica Polona.

Characterization of Antibodies That Inhibit HIV gp120 Antigen Processing and Presentation

M. Gorny, James E. Robinson, Yuxian He, 2005, Retrovirology.

Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.

S. Zolla-Pazner, M. Gorny, D. Tyler, 1990, Journal of immunology.

Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.

Y. Masuho, M. Gorny, E. Hersh, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain.

S. Zolla-Pazner, M. Gorny, J. Patton, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins.

S. Zolla-Pazner, M. Gorny, Constance A U Williams, 2009, Human antibodies.

The C108g Epitope in the V2 Domain of gp120 Functions as a Potent Neutralization Target When Introduced into Envelope Proteins Derived from Human Immunodeficiency Virus Type 1 Primary Isolates

S. Zolla-Pazner, M. Gorny, A. Pinter, 2005, Journal of Virology.

Effect of Soluble CD4 on Exposure of Epitopes on Primary, Intact, Native Human Immunodeficiency Virus Type 1 Virions of Different Genetic Clades

S. Zolla-Pazner, M. Gorny, P. Nyambi, 2001, Journal of Virology.

Anti-V2 Antibody Deficiency in Individuals Infected With HIV-1

S. Zolla-Pazner, M. Gorny, M. Totrov, 2018, bioRxiv.

Model-based optimization of infectivity parameters: a study of the early epidemic in San Francisco.

M. Gorny, D. Ahlgren, A. C. Stein, 1990, Journal of acquired immune deficiency syndromes.

Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function

S. Zolla-Pazner, M. Gorny, C. Bailey-Kellogg, 2014, AIDS.

Malignancy associated with antinuclear antibodies.

M. Gorny, K. Jarczewska, J. Żeromski, 1972, Lancet.

Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies

S. Zolla-Pazner, M. Gorny, T. Palker, 1991, Journal of virology.

Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes.

P. Jagodziński, M. Gorny, A. Sieron, 1996, Virology.

Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1

S. Zolla-Pazner, M. Gorny, J. Atkinson, 1995, The Journal of experimental medicine.

Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients

M. Gorny, T. Quinn, A. Nadas, 2017, Journal of Clinical Microbiology.

Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6

S. Zolla-Pazner, M. Gorny, A. Nadas, 2001, Journal of Virology.

Immunotyping of Human Immunodeficiency Virus Type 1 (HIV): an Approach to Immunologic Classification of HIV

S. Zolla-Pazner, M. Gorny, A. Nadas, 1999, Journal of Virology.

Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu+ by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins

Susan Zolla-Pazner, Hermann Katinger, Joseph Sodroski, 1998, Journal of Virology.

Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins.

D R Burton, C. Barbas, J. Sodroski, 1997, AIDS research and human retroviruses.

Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor

S. Zolla-Pazner, M. Gorny, D. Littman, 1997, Journal of virology.

Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection

M. Gorny, X. Kong, Shixia Wang, 2018, Journal of Virology.

Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1

S. Zolla-Pazner, M. Gorny, C. Bona, 1989, Journal of virology.

Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

S. Zolla-Pazner, M. Gorny, E. Emini, 1994, Journal of virology.

Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies

S. Zolla-Pazner, M. Gorny, S. Laal, 1994, Journal of virology.

Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody

S. Zolla-Pazner, M. Gorny, E. Emini, 1992, Journal of virology.

Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120.

S. Zolla-Pazner, M. Gorny, C. Münz, 2000, AIDS research and human retroviruses.

A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier

S. Zolla-Pazner, M. Gorny, J. Berman, 2016, AIDS.

Immune Correlates of Disease Progression in Linked HIV-1 Infection

S. Zolla-Pazner, M. Gorny, D. Kaufmann, 2019, Front. Immunol..

Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.

B. Korber, P. Hraber, H. Liao, 2015, Cell host & microbe.

Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection

S. Munir Alam, Susan Zolla-Pazner, Barton F. Haynes, 2007, Journal of Virology.

Human Immunodeﬁciency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection (cid:1)

H. Liao, Laura L. Sutherland, B. Haynes, 2007 .

The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection

S. Zolla-Pazner, M. Gorny, Yuxian He, 2004, Journal of Virology.

Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays.

J. Moore, D. Ho, J. Robinson, 1994, Journal of acquired immune deficiency syndromes.

Generation of Neutralizing Human Monoclonal Antibodies against Parvovirus B19 Proteins

S. Zolla-Pazner, M. Gorny, N. Young, 1999, Journal of Virology.

Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.

S. Zolla-Pazner, M. Gorny, A. Buchbinder, 1993, Journal of immunology.

Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

S. Zolla-Pazner, M. Gorny, H. Sheppard, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Association of Diverse Genotypes and Phenotypes of Immune Cells and Immunoglobulins With the Course of HIV-1 Infection

M. Gorny, Liuzhe Li, Yan Liu, 2018, Front. Immunol..

Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.

S. Zolla-Pazner, M. Gorny, C. Hioe, 1997, International immunology.

Ro52 autoantibodies arise from self-reactive progenitors in a mother of a child with neonatal lupus.

M. Gorny, J. Buyon, R. Clancy, 2017, Journal of autoimmunity.

Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

Raphael Gottardo, Hongmei Gao, Bette T. Korber, 2013, Journal of Virology.

Commonly Induced upon Infection Isolates to Neutralization by Antibodies Human Immunodeficiency Virus Type 1 Regulator of the Sensitivity of Primary The V 1 / V 2 Domain of gp 120 Is a Global

S. Zolla-Pazner, M. Gorny, Yuxian He, 2004 .

Characterization of the Outer Domain of the gp120 Glycoprotein from Human Immunodeficiency Virus Type 1

J. Sodroski, S. Zolla-Pazner, M. Gorny, 2004, Journal of Virology.

T-lymphocyte subsets and immunoglobulin concentrations in bronchoalveolar lavage of patients with sarcoidosis and high and low intensity alveolitis.

M. Gorny, W. Bauer, H. Baumann, 1985, The American review of respiratory disease.

Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1

Baoshan Zhang, Peter D. Kwong, John R. Mascola, 2010, Journal of Virology.

Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set.

S. Zolla-Pazner, M. Gorny, I. Wilson, 2008, Acta crystallographica. Section D, Biological crystallography.

Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.

R. Abagyan, S. Zolla-Pazner, M. Gorny, 2010, Virology.

Inhibition of Human Immunodeficiency Virus Type 1 gp120 Presentation to CD4 T Cells by Antibodies Specific for the CD4 Binding Domain of gp120

S. Zolla-Pazner, M. Gorny, D. Nixon, 2001, Journal of Virology.

Search for antiviral functions of potentially protective antibodies against V2 region of HIV-1

M. Gorny, 2020, Human vaccines & immunotherapeutics.

Local monoclonal immunoglobulin production in cancer patient

M. Gorny, J. Żeromski, 1975, Experientia.

A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

S. Zolla-Pazner, M. Gorny, A. Nadas, 2015, Molecular immunology.

Immunoprophylaxis against Mother-to-Child Transmission of HIV-1

S. Zolla-Pazner, M. Gorny, 2006, PLoS medicine.

Mapping of Epitopes Exposed on Intact Human Immunodeficiency Virus Type 1 (HIV-1) Virions: a New Strategy for Studying the Immunologic Relatedness of HIV-1

S. Zolla-Pazner, M. Gorny, G. van der Groen, 1998, Journal of Virology.

Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction.

J. Sodroski, S. Zolla-Pazner, M. Gorny, 1992, Virology.

Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure

S. Zolla-Pazner, M. Gorny, M. Totrov, 2011, PLoS ONE.

Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1.

S. Zolla-Pazner, M. Gorny, R. Redfield, 1994, Journal of immunology.

V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers

M. Gorny, R. Duerr, 2019, Vaccines.

Recognition by Human Monoclonal Antibodies of Free and Complexed Peptides Representing the Prefusogenic and Fusogenic Forms of Human Immunodeficiency Virus Type 1 gp41

S. Zolla-Pazner, M. Gorny, 2000, Journal of Virology.

Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001

H. Liao, M. Gorny, D. Montefiori, 2016, Journal of Virology.

Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner

S. Zolla-Pazner, M. Gorny, M. Robert-Guroff, 2017, Journal of Virology.

Distinct Mechanisms Regulate Exposure of Neutralizing Epitopes in the V2 and V3 Loops of HIV-1 Envelope

S. Zolla-Pazner, M. Gorny, A. Nadas, 2014, Journal of Virology.

Conserved structural elements in the V3 crown of HIV-1 gp120

Timothy Cardozo, Maxim Totrov, Susan Zolla-Pazner, 2010, Nature Structural &Molecular Biology.

Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.

Robyn L Stanfield, Ian A Wilson, Susan Zolla-Pazner, 2004, Structure.

Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies.

S. Zolla-Pazner, M. Gorny, G. Landucci, 1995, AIDS research and human retroviruses.

Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry

J. Mascola, S. Zolla-Pazner, M. Gorny, 1995, Journal of virology.

Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120.

S. Zolla-Pazner, M. Gorny, T. Fuerst, 1992, AIDS research and human retroviruses.

Correction: Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication

A. Casadevall, S. Zolla-Pazner, M. Gorny, 2012, PLoS ONE.

Targeted Killing of Virally Infected Cells by Radiolabeled Antibodies to Viral Proteins

A. Casadevall, S. Zolla-Pazner, M. Gorny, 2006, PLoS medicine.

Alloantibodies, autoantibodies, and immune complexes in patients with lung cancer

M. Gorny, M. Ławniczak, E. Kaczmarek, 2007, Lung.

Identification of a New Quaternary Neutralizing Epitope on Human Immunodeficiency Virus Type 1 Virus Particles

L. Stamatatos, S. Zolla-Pazner, M. Gorny, 2005, Journal of Virology.

The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope

J. Mascola, S. Zolla-Pazner, M. Gorny, 2004, Journal of Virology.

Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades

Abraham Pinter, Susan Zolla-Pazner, S. Zolla-Pazner, 2002, Journal of Virology.

Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV

S. Zolla-Pazner, M. Gorny, X. Kong, 2014, Journal of Virology.

Conserved and Exposed Epitopes on Intact, Native, Primary Human Immunodeficiency Virus Type 1 Virions of Group M

S. Zolla-Pazner, M. Gorny, A. Nadas, 2000, Journal of Virology.

CYTOTOXICITY IN NORMAL AND MULTIPLE-SCLEROSIS SERA AGAINST MOUSE CELLS EXPRESSING THETA-ANTIGEN

M. Gorny, H. Koprowski, T. Tachovsky, 1975, The Lancet.

Reinterpretation of human immunodeficiency virus western blot patterns.

S. Zolla-Pazner, M. Gorny, A. Pinter, 1989, The New England journal of medicine.

Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

S. Zolla-Pazner, M. Gorny, A. Nadas, 2009, Molecular immunology.

Characterization by serial deletion competition ELISAs of HIV-1 V3 loop epitopes recognized by monoclonal antibodies.

S. Zolla-Pazner, M. Gorny, J. Binley, 1996, Molecular immunology.

Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1

J. Sodroski, J. Moore, S. Zolla-Pazner, 1994, Journal of virology.

Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals.

Ashutosh Biswas, Susan Zolla-Pazner, Michael S Seaman, 2013, Virology.

A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.

J. Mascola, S. Zolla-Pazner, M. Gorny, 1998, AIDS research and human retroviruses.

Human Immunodeficiency Virus (HIV) Envelope Binds to CXCR4 Independently of CD4, and Binding Can Be Enhanced by Interaction with Soluble CD4 or by HIV Envelope Deglycosylation

Susan Zolla-Pazner, J. Hoxie, S. Zolla-Pazner, 1998, Journal of Virology.

Cross-Clade Neutralizing Activity of Human Anti-V3 Monoclonal Antibodies Derived from the Cells of Individuals Infected with Non-B Clades of Human Immunodeficiency Virus Type 1

S. Zolla-Pazner, M. Gorny, A. Nadas, 2006, Journal of Virology.

Crystal Structures of Human Immunodeficiency Virus Type 1 (HIV-1) Neutralizing Antibody 2219 in Complex with Three Different V3 Peptides Reveal a New Binding Mode for HIV-1 Cross-Reactivity

S. Zolla-Pazner, M. Gorny, I. Wilson, 2006, Journal of Virology.

Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins.

S. Zolla-Pazner, M. Gorny, T. Vancott, 2000, Virology.

Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.

S. Zolla-Pazner, M. Gorny, N. Michael, 1997, Journal of immunology.

Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

S. Zolla-Pazner, M. Gorny, James E. Robinson, 2014, Virology.

Changes of Oxytocin and Serotonin Values in Dialysis Patients after Animal Assisted Activities (AAAs) with a Dog—A Preliminary Study

M. Gorny, P. Formisano, M. Sansone, 2019, Animals : an open access journal from MDPI.

A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque.

N. Haigwood, M. Gorny, X. Kong, 2021, Vaccine.

Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates

S. Zolla-Pazner, M. Gorny, D. Dimitrov, 2002, Journal of Virology.

Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies.

J. Sodroski, S. Zolla-Pazner, M. Gorny, 2009, AIDS research and human retroviruses.

Polymerase chain reaction-based assay for antibody-mediated neutralization of HIV-1 reveals a population of nonneutralized virus undetected by conventional p24 assay.

S. Zolla-Pazner, M. Gorny, J. Bandres, 2000, Journal of acquired immune deficiency syndromes.

, Rajnish Loops of HIV-1 Envelope Neutralizing Epitopes in the V 2 and V 3 Distinct Mechanisms Regulate Exposure of

S. Zolla-Pazner, M. Gorny, A. Nadas, 2014 .

Expression, purification, and isotope labeling of the Fv of the human HIV-1 neutralizing antibody 447-52D for NMR studies.

M. Gorny, A. Zvi, R. Levy, 2003, Protein expression and purification.

CLINICAL PHARMACOKINETICS CONCEPTS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS OF PHYTOMEDICINES IN SOME DEVELOPING COUNTRIES

M. Gorny, A. Nanfack, J. Fokam, 2018 .

Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis

S. Zolla-Pazner, M. Gorny, C. Hager-Braun, 2010, Journal of the American Society for Mass Spectrometry.

The light chain of antibodies specific to the V2 region of HIV-1 can determine their function.

M. Gorny, X. Kong, Xiao-hong Wang, 2021, Human immunology.

Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens.

S. Zolla-Pazner, M. Gorny, M. Sukumaran, 2009, Structure.

Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies

J. Mascola, L. Stamatatos, S. Zolla-Pazner, 2011, Journal of Virology.

Quaternary Epitope Specificities of Anti-HIV-1 Neutralizing Antibodies Generated in Rhesus Macaques Infected by the Simian/Human Immunodeficiency Virus SHIVSF162P4

L. Stamatatos, S. Zolla-Pazner, M. Gorny, 2010, Journal of Virology.

Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001

M. Gorny, D. Montefiori, Shixia Wang, 2016, Journal of Virology.

S. Zolla-Pazner, M. Gorny, James E. Robinson, 2011, Journal of Virology.

Evaluation of phenotype of mononuclear host cells isolated from primary tumour and peripheral blood of patients with laryngeal carcinoma.

M. Gorny, J. Żeromski, A. Kruk-Zagajewska, 1988, Acta oto-laryngologica.

Immunoconjugates containing ricin A chain and either human anti-gp41 or CD4 kill H9 cells infected with different isolates of HIV, but do not inhibit normal T or B cell function.

S. Zolla-Pazner, M. Gorny, V. Ghetie, 1990, Journal of acquired immune deficiency syndromes.